Participants 0 111 3
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
Participants 114 286 7
Grades 2-4 acute graft-versus-host disease (GVHD) occurs in approximately 35% of matched, related donor (MRD) allogeneic hematopoietic cell transplantation (HCT) recipients
Participants 583 691 7
114-day grades 2-4 acute GVHD-free survival using an intention-to-treat analysis of 304 randomized subjects.
